Menu
GeneBe

rs199469707

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong

The NM_001044385.3(TMEM237):​c.52C>T​(p.Arg18Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000718 in 1,602,646 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: 𝑓 0.000059 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000073 ( 0 hom. )

Consequence

TMEM237
NM_001044385.3 stop_gained

Scores

4
2
1

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:11

Conservation

PhyloP100: 4.80
Variant links:
Genes affected
TMEM237 (HGNC:14432): (transmembrane protein 237) The protein encoded by this gene is a tetraspanin protein that is thought to be involved in WNT signaling. Defects in this gene are a cause of Joubert syndrome-14. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. There are 25 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-201640915-G-A is Pathogenic according to our data. Variant chr2-201640915-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 31180.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-201640915-G-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
TMEM237NM_001044385.3 linkuse as main transcriptc.52C>T p.Arg18Ter stop_gained 2/13 ENST00000409883.7
TMEM237NM_152388.4 linkuse as main transcriptc.28C>T p.Arg10Ter stop_gained 2/13

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
TMEM237ENST00000409883.7 linkuse as main transcriptc.52C>T p.Arg18Ter stop_gained 2/135 NM_001044385.3 P4Q96Q45-1

Frequencies

GnomAD3 genomes
AF:
0.0000592
AC:
9
AN:
152010
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000132
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000607
AC:
15
AN:
247028
Hom.:
0
AF XY:
0.0000448
AC XY:
6
AN XY:
133946
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000332
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000125
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000731
AC:
106
AN:
1450636
Hom.:
0
Cov.:
30
AF XY:
0.0000763
AC XY:
55
AN XY:
720708
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000118
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000915
Gnomad4 OTH exome
AF:
0.0000668
GnomAD4 genome
AF:
0.0000592
AC:
9
AN:
152010
Hom.:
0
Cov.:
33
AF XY:
0.0000539
AC XY:
4
AN XY:
74232
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000132
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000926
Hom.:
0
Bravo
AF:
0.0000416
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000368
AC:
3
ExAC
AF:
0.0000662
AC:
8

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Joubert syndrome 14 Pathogenic:6
Pathogenic, no assertion criteria providedliterature onlyOMIMOct 05, 2012- -
Pathogenic, criteria provided, single submitterclinical testingInvitaeJul 23, 2022This sequence change creates a premature translational stop signal (p.Arg18*) in the TMEM237 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TMEM237 are known to be pathogenic (PMID: 22152675). This variant is present in population databases (rs199469707, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with Joubert syndrome (PMID: 22152675, 22981120). It is commonly reported in individuals of Hutterite ancestry (PMID: 22152675, 22981120). ClinVar contains an entry for this variant (Variation ID: 31180). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityDec 29, 2021- -
Pathogenic, criteria provided, single submitterclinical testingRady Children's Institute for Genomic Medicine, Rady Children's Hospital San DiegoMay 04, 2018This nonsense variant found in exon 2 of 13 is predicted to result in loss of normal protein function. This variant has been previously reported as a homozygous change in ten Canadian Hutterite patients with intellectual disability, a characteristic facial appearance, encephalocele, coloboma, renal disease, and additional features consistent with a diagnosis of a Joubert syndrome related disorder (PMID: 22152675, 17603801). The variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.005% (15/275258) and thus is presumed to be rare. Based on the available evidence, c.52C>T (p.Arg18Ter) variant is classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingVictorian Clinical Genetics Services, Murdoch Childrens Research InstituteFeb 02, 2022Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Joubert syndrome 14 (MIM#614424). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (16 heterozygotes, 0 homozygotes). (SP) 0701 - Other premature termination variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. Many NMD-predicted variants in this gene have been reported as likely pathogenic/pathogenic (ClinVar). (SP) 0802 - This variant has moderate previous evidence of pathogenicity in unrelated individuals. It has been reported as homozygous in many related Hutterite individuals with severe Joubert syndrome related disorder (PMIDs: 17603801, 22152675). It has been described as a founder variant in Hutterite individuals (PMID: 31710777). It has also been reported as pathogenic in ClinVar, however ethnicity of those individuals were not provided. (SP) 1001 - This variant has strong functional evidence supporting abnormal protein function. Functional studies using patient fibroblast line showed defective ciliogenesis and pairing of centrioles, and reduced TMEM237 expression level (PMID: 22152675). (SP) 1205 - This variant has been shown to be maternally inherited. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
Pathogenic, criteria provided, single submitterclinical testingMolecular Genetics, Royal Melbourne HospitalApr 22, 2022This sequence change creates a premature termination codon at position 18 in exon 2 (of 13) of TMEM237 ,p.(Arg18*). It is expected to result in an absent or disrupted protein product, and loss of function is the established mechanism of disease for this gene (PMID: 22152675). The variant is present in a large population cohort at a frequency of 0.006%, which is consistent with a recessive condition (rs199469707, 16/278,360 alleles, 0 homozygotes in gnomAD v2.1). The variant has been identified in individuals with Joubert syndrome, and segregates with the condition in the homozygous state in multiple related Canadian Hutterite families. Fibroblast cell lines from homozygous cases show loss of TMEM237 expression, and defective ciliogenesis and pairing of centrioles (PMID: 22152675). Based on the classification scheme RMH Modified ACMG Guidelines v1.4.0, this variant is classified as PATHOGENIC. Following criteria are met: PVS1, PP1_Strong, PM2_Supporting, PP4. -
not provided Pathogenic:3
Pathogenic, no assertion criteria providedclinical testingGenome Diagnostics Laboratory, University Medical Center Utrecht-- -
Pathogenic, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Pathogenic, no assertion criteria providedclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center-- -
Joubert syndrome and related disorders Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMay 06, 2022Variant summary: TMEM237 c.52C>T (p.Arg18X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic within ClinVar. The variant allele was found at a frequency of 6.1e-05 in 247028 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in TMEM237 causing Joubert Syndrome And Related Disorders (6.1e-05 vs 0.0004), allowing no conclusion about variant significance. The variant was found at an 8% carrier frequency rate within the Hutterite communities of Canada and the Northern United States, indicating a founder effect for the variant. Subsequently, c.52C>T has been reported in the literature in multiple homozygous individuals affected with Joubert Syndrome And Related Disorders from Hutterite communities (Huang_2011). The variant was also found in at least one compound heterozygous, presumably non-Hutterite individual (Clark_2019). These data indicate that the variant is very likely to be associated with disease. Huang_2011 has shown that fibroblasts homozygous for the variant have defects in ciliogenesis with no detectable ciliated cells as seen via microscopy. Huang_2011 also showed that the variant causes large reductions (98%) in TMEM237 transcripts and fibroblasts with the variant had dysregulated Wnt signaling. Three ClinVar submitters have assessed the variant since 2014: all three classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Familial aplasia of the vermis Pathogenic:1
Pathogenic, no assertion criteria providedcurationGeneReviewsMar 29, 2012- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.48
D
BayesDel_noAF
Pathogenic
0.60
CADD
Pathogenic
41
DANN
Uncertain
1.0
Eigen
Pathogenic
0.83
Eigen_PC
Pathogenic
0.69
FATHMM_MKL
Uncertain
0.96
D
MutationTaster
Benign
1.0
A;A
Vest4
0.25
GERP RS
3.9

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.060
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs199469707; hg19: chr2-202505638; COSMIC: COSV53804415; COSMIC: COSV53804415; API